Patients with group A beta-hemolytic streptococcal pharyngitis have classic symptoms of tonsillar swelling/exudates, tender anterior cervical lymphadenopathy, with no cough but with fever of >38ºC.
Clinical features suggestive of a viral etiology are conjunctivitis, absence of fever, coryza, cough, diarrhea, anterior stomatitis, hoarseness, discrete ulcerative lesions, rhinorrhea and viral exanthem and/or enanthem.
Antibiotics will not be needed for every patient that presents with sore throat but it should not be withheld if the clinical condition is severe or group A beta-hemolytic streptococca is suspected.

Patient Education

  • Provide educational material about non-streptococcal causes of sore throats & home remedies that the patient may use
  • Patient should be instructed to follow-up if the symptoms worsen or if they persist beyond 5-7 days
  • Advise patient to eliminate close contact with other people to minimize transmission of the disease
    • Patients are infectious 2-5 days before symptom onset, during the illness, & for a week after if untreated

Group A Beta-Hemolytic Streptococci Suspected or Confirmed

  • Instruct the patient to remain at home until at least 24 hours of antimicrobial therapy has been received to minimize transmission of disease
  • Emphasize the importance of adhering to the prescribed medication regimen
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Editor's Recommendations
Most Read Articles
16 Dec 2016
KEYTRUDA – Pembrolizumab 100 mg/4 mL soln for inj – Merck Sharp & Dohme
30 Jan 2018
Subtype and gender of attention deficit hyperactivity disorder (ADHD) differentially impact smoking initiation and escalation, a recent study suggests.
03 May 2016
The use of house dust mite (HDM) sublingual allergen immunotherapy (SLIT) tablet lowers the risk of moderate or severe asthma exacerbation, according to a recent study.
15 May 2017
New drug applications approved by US FDA as of 1 - 15 May 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.